MedTrace Logo

Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes

NCT00286455 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 329

Last updated 2012-02-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), in adults with type 2 diabetes.

Conditions

Interventions

DRUG

Alogliptin

Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.

DRUG

Alogliptin

Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.

DRUG

Placebo

Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.

Sponsors & Collaborators

Principal Investigators

  • VP Biological Sciences · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Chile
  • Czechia
  • Dominican Republic
  • Germany
  • Guatemala
  • Hungary
  • India
  • Mexico
  • Netherlands
  • New Zealand
  • Peru
  • Poland
  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00286455 on ClinicalTrials.gov